Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.

Blood - 19 Nov 2015

Cargo Catherine A, Rowbotham Nicola, Evans Paul A, Barrans Sharon L, Bowen David T, Crouch Simon, Jack Andrew S

Abstract excerpt

The diagnosis of myelodysplastic syndromes (MDS) remains problematic due to the subjective nature of morphologic assessment. The reported high frequency of somatic mutations and increased structural variants by array-based cytogenetics have provided potential objective markers of disease; however, this has been complicated by reports of similar abnormalities in the healthy population. We aimed to identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Risk Factors

Share to Survival Rate

Source

Identifiers

PMID: 26392596
DOI: 10.1182/blood-2015-08-663237

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.PMID 26392596Read ↗

Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.Semantic proximity Read ↗

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progressionSemantic proximity Read ↗

Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms.Semantic proximity Read ↗

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Semantic proximity Read ↗

The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes.Semantic proximity Read ↗

De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features.Semantic proximity Read ↗

Clinical and biological implications of driver mutations in myelodysplastic syndromes.Semantic proximity Read ↗

The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.Semantic proximity Read ↗

Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms.Semantic proximity Read ↗

Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.Semantic proximity Read ↗

Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia.Semantic proximity Read ↗

Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.